Kyverna Therapeutics is a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases. The company's lead product candidate, mivocabtagene autoleucel (miv-cel or KYV-101), is an autologous CD19-targeting CAR T-cell therapy designed to deeply deplete B cells to achieve durable, treatment-free remission. Kyverna is advancing miv-cel in neuroimmunology indications, including stiff person syndrome and generalized myasthenia gravis, with a planned biologics license application submission for stiff person syndrome in the first half of 2026. The company is also conducting clinical trials in progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis. Kyverna is developing next-generation CAR T-cell technologies and rapid manufacturing processes, such as KYV-102, to expand patient access and broaden its pipeline into additional autoimmune indications.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage kyvernatx.com
Sector Healthcare IR page ir.kyvernatx.com
Tags
cell therapy, car t-cell therapy, autoimmune diseases, neuroimmunology, stiff person syndrome, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, lupus nephritis, systemic sclerosis, b-cell depletion, autologous therapy, mivocabtagene autoleucel, miv-cel, KYV-101, KYV-102, KYSA-8, KYSA-6
Press page —

Metrics

Valuation  
Market cap $ 425.254M
Market cap (USD) $ 425.254M
P/E -2.46
PEG —
P/BV 3.19
P/S 60.53
P/OCF -2.82
P/FCF -2.77
Dividend yield —
Turnover / mcap —
Returns  
ROE -64.7%
ROI -62.8%
ROIC -49.6%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 18.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 84
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue — — 0 7.025M 5.656M
Net profit -161.307M -127.477M -60.366M -28.893M -26.35M
Free cash flow -153.717M -116.455M -53.031M -36.881M -23.444M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 9.4 3.74 — — —
Price performance 12m 1.51 — — — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) — — 24.7M
Lease liabilities (USD) 9.08M 8.24M 4.29M
Cash and deposits (USD) 34.6M 96.6M 124M
Right-of-use assets (USD) 6.49M 6.47M 3.57M
Net debt (borrowings + leases - cash) (USD) — — -95.1M
Cash flow detail
Operating cash flow (USD) -52.4M -114M -154M
Purchases of property, plant and equipment (USD) -621,000 -2.21M -5,000
Change in payables (cash effect) (USD) 4.08M 736,000 543,000
Interest paid (cash effect) (USD) -187,000 -142,000 -415,000
Income taxes paid (cash effect) (USD) — 0.00 0.00
Share-based compensation (USD) 2.22M 8.36M 10.1M
Free cash flow (OCF - PPE - intangibles) (USD) -53M -116M -154M
Income detail
Research and development expense (USD) 49.9M 112M 134M
Total comprehensive income (USD) -60.3M -127M -161M
Comprehensive income to owners (USD) -60.3M -127M -161M
Reported Mar 27, 2025 Mar 26, 2026 Aug 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

BLA submission for miv-cel in SPS completed with request for priority review

Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first approved therapy for SPS and first approved CAR-T therapy in autoimmune disease

KYSA-6 Phase 3 gMG trial enrollment on-track for completion in mid-2027

Miv-cel’s clinical profile continues to set the benchmark for autoimmune CAR T, demonstrating durable clinical benefit and a consistent, well-tolerated safety profile across multiple neurologic autoimmune indications

EMERYVILLE, Calif., November 12, 2026 -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today reported portfolio progress and financial results for the third quarter ended September 30, 2026.

“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies,” said Warner Biddle, Chief Executive Officer of Kyverna.

October 23, 2026

PDF Version

Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies

Durable results extending beyond two years in the first patient treated

Consistent, well-tolerated safety profile with no high-grade CRS and no cases of ICANS or IEC-HS

RMAT designation granted in treatment of non-active secondary progressive multiple sclerosis (naSPMS); update on development strategy expected by early 2027

EMERYVILLE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced updated data from a Phase 1 investigator-initiated trial (IIT) of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with progressive multiple sclerosis (PMS). The data will be shared today in an oral presentation at MS Toronto 2026, the joint ACTRIMS-ECTRIMS meeting.

“There remains a substantial unmet need for therapies that can meaningfully alter the course of progressive multiple sclerosis,” said Jeffrey Dunn, MD, Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology at Stanford University. “In this early-phase study, miv-cel demonstrated encouraging tolerability, with evidence of CAR T-cell penetration into the central nervous system and biologic findings consistent with an immune reset. Importantly, we also observed sustained improvements in measures of neurologic disability and patient-reported function among evaluable participants. While these preliminary findings require confirmation in larger controlled trials, they provide an important proof of concept that miv-cel may offer a potential novel approach to treating progressive multiple sclerosis.”

Stanford Oral Presentation Title: Safety and Preliminary Efficacy of CD-19 Directed CAR T-Cell Therapy in Progressive Multiple Sclerosis: A Phase 1 Study **Presenter:**Jeff Dunn, M.D., Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology, Stanford University Date & Time: Friday, October 23, 2026, 11:05 – 11:15 AM ET

Stanford University is conducting an open-label, Phase 1, single-center study of miv-cel in patients with non-relapsing progressive multiple sclerosis, either secondary progressive MS (SPMS) or primary progressive MS (PPMS). Six patients were treated with either 33M (n=3) or 100M (n=3) CAR T-cell dose levels using a bendamustine lymphodepleting (LD) regimen.

The oral presentation features updated data from six patients with available efficacy data from five patients, with follow-up of more than two years in the longest-treated patient. Key highlights include:

Efficacy:

  • All five patients with available data demonstrated stable to improved expanded disability status scale scores (EDSS) as of last follow-up, with the majority (4/5) showing sustained clinical benefit through one year.

  • Four patients with more than one-year of follow-up sustained improvement without further need for chronic immunotherapies. The first patient treated with miv-cel achieved sustained clinical benefit beyond two years.

Biological activity:

  • Robust CAR T-cell expansion detected in peripheral blood and penetration in cerebrospinal fluid (CSF), with peak levels at approximately day 14.

  • Complete depletion of CD19-positive peripheral B cells was achieved in all participants, followed by repopulation beginning at month 3, consistent with the emergence of naïve B cells, supporting evidence of immune reset.

  • Additional biomarker data, including CSF oligoclonal bands and kappa free light chain, continue to support favorable immunological impact at one year.

Safety:

  • Consistent, well-tolerated safety profile with no high-grade CRS and no reported cases of ICANS or IEC-HS.

“We are encouraged by the long-term durability and safety results with miv-cel in progressive multiple sclerosis, which add to the strong body of evidence supporting miv-cel’s transformative potential across neurologic autoimmune diseases,” said Naji Gehchan, Chief Medical and Development Officer of Kyverna Therapeutics. “The consistent, durable clinical benefit and well-tolerated safety profile observed across our indications are underpinned by miv-cel’s unique construct, specifically developed by Kyverna in autoimmune disease to enable immune reset by deeply and broadly depleting B-cells with a single dose. With our RMAT designation, we look forward to working with the FDA on our development plan in progressive multiple sclerosis and providing an update by early 2027.”

About miv-cel (mivocabtagene autoleucel, KYV-101) Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.

About Multiple Sclerosis Multiple sclerosis is a chronic autoimmune disease causing neurodegeneration, in which patients can experience a range of symptoms including blurred vision, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, and, in severe cases, the inability to walk or stand, B cells play a significant role in MS by producing autoantibodies that attack the protective sheath around the nerves, activating T cells, and increasing inflammation. Current disease-modifying treatments for MS aim to reduce the frequence of disease relapse and delay a progression of disability, but the disease remains a chronic condition that will progressively worsen for most patients.

About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).

Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy's potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.

Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: miv-cel’s potential to meaningfully alter the course of, or offer a novel approach to treating, progressive multiple sclerosis; miv-cel’s transformative potential across neurologic autoimmune diseases; Kyverna’s development plans in progressive multiple sclerosis and expected timing for providing an update on its development strategy for multiple sclerosis; the potential for miv-cel to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose or to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases; Kyverna’s pipeline opportunities; and Kyverna’s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; risks related to the timing and outcome of regulatory submissions and interactions with the FDA; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that topline results may change following further analysis or differ from final results; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

October 21, 2026

PDF Version

Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies

Deep B-cell depletion demonstrated with a single dose supports the potential for broad immune reset enabled by miv-cel's unique construct

Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS in one-year follow-up

Data further strengthens SPS BLA package and supports potential for miv-cel to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune diseases

EMERYVILLE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced the full one-year data set from KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS). The data will be presented today at MS Toronto 2026, the joint ACTRIMS-ECTRIMS meeting.

“The totality of the one-year durability data from the KYSA-8 trial is very encouraging and suggests miv-cel has the potential to fundamentally change how we treat stiff person syndrome, a progressive, disabling disease with no approved therapies,” said Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine, Céline Dion Foundation Endowed Chair, and lead investigator of the KYSA-8 trial. “The positive primary endpoint results, together with the secondary and exploratory endpoint data, highlight the full clinical benefit of miv-cel with a single dose. Through one year, patients experienced significant improvements across multiple measures of disease burden, including disability, mobility, stiffness, hypersensitivity, physical functioning and mental health, with a well-tolerated safety profile.”

Poster Presentation: Title: 1-Year Analysis of KYSA-8: the Pivotal, Multicenter, Phase 2 Study of Miv-cel (Mivocabtagene Autoleucel; Formerly KYV-101) CD19 CAR T-Cell Therapy in Stiff Person Syndrome **Presenter:**Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine Poster ID: P0364 **Date & Time:**Wed., October 21, 2026, 4:30 – 6:30 PM ET

As reported at AAN 2026, the primary endpoint and all key secondary endpoints were achieved with statistical significance in KYSA-8. The one-year durability data being presented today further strengthens these positive results.

Efficacy highlights from one-year follow-up data on 26 patients include:

  • Significant improvement in the timed 25-Foot Walk (T25FW) sustained at one year (p < 0.0001): median improvement from baseline of 46% at week 16 (primary endpoint) and 49% at one year.

  • At 16 weeks and one year after receiving miv-cel, 81% (21/26) and 77% (20/26) of patients achieved clinically meaningful improvement (≥20% reduction from baseline) in T25FW, respectively, demonstrating sustained benefit for the vast majority of patients.

  • Over one-third of patients completed T25FW in <5 seconds, comparable to a typical time for healthy adults.

  • Of the 12 patients requiring a walking aid prior to treatment, 67% (8/12) continue to not require assistance.

  • 92% (24/26) of patients remained free of chronic immunotherapies for SPS.

  • At one year, the trial continued to meet all secondary endpoints, with significant mean improvements from baseline in Modified Rankin Scale, Hauser Ambulation Index, Distribution-of-Stiffness and Heightened Sensitivity Scale, of -1.0 (p = .0003), -1.7 (1.38; p < .0001), -1.6 (1.75; p < .0001) and -2.8 (2.11; p < .0001), respectively.

Exploratory endpoints, including additional efficacy measures continue to support miv-cel’s differentiated clinical profile:

  • In the 6-minute walk test, responses deepened over time, with the median improvement in walking distance increasing from 89 meters at the 16-week primary endpoint measurement to 119 meters at one year, a nearly 6-fold improvement over the clinical minimally important change of 20 meters.

  • Sustained clinical benefit at one year in physical functioning and mental health, comparable to healthy adults, across the 36-item short form health survey.

  • B-cell reconstitution was observed with sustained efficacy and antibody reduction.

Miv-cel continued to demonstrate a well-tolerated safety profile, supporting its potential for outpatient administration:

  • No high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).

  • Grade 3/4 neutropenia, an expected adverse event (AE) with lymphodepletion and CAR T-cell therapies, was observed in five patients and was manageable.

  • Serious treatment-related AEs occurred in three patients, all of which have fully resolved.

“This is a remarkable data set, demonstrating consistent and durable clinical benefit across primary, secondary, and exploratory endpoints, with a well-tolerated safety profile,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “These results reinforce miv-cel’s potential best-in-class clinical profile, which may meaningfully change the trajectory of stiff person syndrome with a single dose, while allowing patients to remain free of chronic immunosuppressive therapies. We look forward to bringing this transformative therapy to patients as quickly as possible.”

About KYSA-8 Registrational Clinical Trial KYSA-8 is a single-arm registrational Phase 2 trial in which 26 adult patients with SPS, who had an inadequate response to at least one immunotherapy treatment, received a single dose of miv-cel. The primary endpoints are the change from baseline in the T25FW at 16 weeks and the incidence and severity of adverse events (AEs). Secondary endpoints measuring disability, stiffness, hypersensitivity, and mobility include the Modified Rankin Scale (mRS), Distribution-of-stiffness Index (DSI), Heightened Sensitivity Scale (HSS), and Hauser Ambulation Index (HAI), respectively.

About miv-cel (mivocabtagene autoleucel, KYV-101) Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.

About Stiff Person Syndrome (SPS) SPS is a rare, progressive neurologic autoimmune disease characterized by muscle stiffness and painful muscle spasms, impacting mobility and gait. Stiffness, rigidity, and spasms in the torso, arms, and legs lead to progressive disability causing up to 80% of patients to lose mobility, requiring walking aid assistance or wheelchair use1-3. SPS has been shown to lead to permanent disability and increased risk of mortality3. Most patients with SPS have antibodies to glutamic acid decarboxylase 65 (GAD65) or the glycine receptor, which disrupt normal inhibitory neurotransmission, contributing to the hallmark symptoms of SPS. There are currently no FDA-approved treatments for SPS. Current treatment options include symptomatic treatments, off-label immunotherapies, such as intravenous immunoglobulin (IVIg), rituximab and plasmapheresis, as well as supportive care and physical, speech, occupational, and psychiatric therapy; however, the majority of patients have inadequate or no response to these treatment options. An estimated 6,000 patients are diagnosed with SPS in the United States4-5.

About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).

Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy's potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.

Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential for a single dose of miv-cel to provide a broad immune reset; miv-cel’s potential to fundamentally change how stiff person syndrome is treated; miv-cel’s potential outpatient administration; miv-cel’s potential best-in-class clinical profile; miv-cel’s potential to meaningfully change the trajectory of stiff person syndrome with a single dose while allowing patients to remain free of chronic immunosuppressive therapies; the potential for miv-cel to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose or to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases; the possibility that miv-cel may be the first approved treatment for patients with SPS or the first approved CAR T-cell therapy for autoimmune diseases; Kyverna’s pipeline opportunities; and Kyverna’s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; risks related to the timing and outcome of regulatory submissions and interactions with the FDA; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that topline results may change following further analysis or differ from final results; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Prompts

Kyverna Therapeutics, Inc. (ticker KYTX), listed in United States.

ETFs Holding Kyverna Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
SURI 1.26% 182,603 $ 858.234K Nov 17, 2026
FSEG 0.05% 349 $ 3,109.59 Jun 30, 2026
VFMO 0.03% 73,493 $ 622.853K Aug 31, 2026
FESM 0.01% 87,942 $ 783.563K Jun 30, 2026
RESM 0.01% 44 $ 392.04 Jun 30, 2026
AVSC 0.01% 66,478 $ 316.435K Nov 16, 2026
DXUV 0.00% 20,315 $ 102.184K Nov 12, 2026
DFAS 0.00% 77,449 $ 389.568K Nov 12, 2026
DFAU 0.00% 12,986 $ 65.32K Nov 12, 2026
DCOR 0.00% 39,687 $ 199.626K Nov 12, 2026
DFAC 0.00% 58,928 $ 296.408K Nov 12, 2026
DFUS 0.00% 9,116 $ 45.853K Nov 12, 2026